Redeye sees a continued positive trajectory for BONESUPPORT, and we believe the stock should trade some +5% up on the report. Sales reached a new record of SEK 54,9m (some 3% above our estimates) and an EBIT of SEK -13,3m (considerably better than we expected; lower administrative and R&D costs’ decreases contributed well to this). Surgeries with CERAMENT continue to increase during the quarter, which is still impacted by the pandemic, implying a potential market share reaping of its existing competitors. We will return with a more detailed note following today’s conference call.
LÄS MER
